All In Biotech

Drug Trial Radar · NCT03512197

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Aug 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 511 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

511

Actual

Start

Jul 20, 2018

Primary completion

Feb 12, 2021

Study completion Feb 12, 2021

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 30, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR\<0.05) AML (FLT3 mutant to wild type signal ratio below the 0.05 clinical cut-off). This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin or idarubicin and cytarabine for induction and intermediate-dose cytarabine for consolidation, and midostaurin single agent post-consolidation therapy in newly diagnosed patients with FLT3-MN (SR\<0.05) AML.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • MidostaurinDrug

    Midostaurin was provided as 25 mg capsules 8PC, was supplied as double-blind in blister packs and taken orally.

  • PlaceboDrug

    Placebo was provided as 25 mg soft gelatin capsules 8PC, was supplied as double-blind in blister packs and taken orally.

  • ChemotherapyDrug

    Along with the study drug/placebo, chemotherapy was given as well: either Daunorubicin or Idarubicin and Cytarabine - all taken by i.v.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event Free Survival (EFS)Time frame: From date of Randomization up to approx. 30 months

Locations

133 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Chicago Medical Center .

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Oregon Health and Science Univ

    Portland, Oregon

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Woolloongabba, Queensland, Australia

  • Novartis Investigative Site

    Prahran, Victoria, Australia

  • Novartis Investigative Site

    Murdoch, Western Australia, Australia

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Antwerp, Belgium

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Roeselare, Belgium

  • Novartis Investigative Site

    São Paulo, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Brno-Bohunice, Czechia

  • Novartis Investigative Site

    Plzen-Bory, Czechia

  • Novartis Investigative Site

    Angers, France

  • Novartis Investigative Site

    Avignon, France

  • Novartis Investigative Site

    Dijon, France

  • Novartis Investigative Site

    Lille, France

  • Novartis Investigative Site

    Nantes, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Bayonne, Bayonne Cedex, France

  • Novartis Investigative Site

    Bad Saarow, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Bochum, Germany

  • Novartis Investigative Site

    Bonn, Germany

  • Novartis Investigative Site

    Braunschweig, Germany

  • Novartis Investigative Site

    Darmstadt, Germany

  • Novartis Investigative Site

    Duisburg, Germany

  • Novartis Investigative Site

    Düsseldorf, Germany

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.